Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management

Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management Familial hypercholesterolemia (FH) is an inherited disorder of lipid metabolism characterized by premature cardiovascular disease. It is one of the most common metabolic disorders affecting humans. There are two clinical manifestations: the milder heterozygous form and more severe homozygous form. Despite posing a significant health risk, FH is inadequately diagnosed and managed. As the clinical outcome is related to the degree and duration of exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels, early treatment is vital. Diagnosis can usually be made using a combination of clinical characteristics such as family history, lipid levels, and genetic testing. Mutations in the gene encoding the LDL receptor (LDLR), apolipoprotein B, the pro-protein convertase subtilisin/kexin 9 (PCSK9), and LDLR adaptor protein are the commonest abnormalities. Early identification and treatment of patients, as well as screening of relatives, helps significantly reduce the risk of premature disease. Although statins remain the first-line therapy in most cases, monotherapy is usually inadequate to control elevated LDL-C levels. Additional therapy with ezetimibe and bile acid sequestrants may be required. Newer classes of pharmacotherapy currently under investigation include lomitapide, mipomersen, and monoclonal antibodies to PCSK9. Lipoprotein apheresis may be required when multiple pharmacotherapies are inadequate, especially in the homozygous form. Effective early detection and treatment of the index individual and initiation of cascade screening will help reduce the complications associated with FH. In this article, we review the disease of FH, complexity of diagnosis and management, and the challenges faced in preventing the significant morbidity and mortality associated with it. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management

Najam, Osman; Ray, Kausik
Cardiology and Therapy , Volume 4 (1) – Mar 14, 2015
Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/familial-hypercholesterolemia-a-review-of-the-natural-history-sNJQoTwTYV
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-015-0037-z
pmid
25769531
Publisher site
See Article on Publisher Site

Abstract

Familial hypercholesterolemia (FH) is an inherited disorder of lipid metabolism characterized by premature cardiovascular disease. It is one of the most common metabolic disorders affecting humans. There are two clinical manifestations: the milder heterozygous form and more severe homozygous form. Despite posing a significant health risk, FH is inadequately diagnosed and managed. As the clinical outcome is related to the degree and duration of exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels, early treatment is vital. Diagnosis can usually be made using a combination of clinical characteristics such as family history, lipid levels, and genetic testing. Mutations in the gene encoding the LDL receptor (LDLR), apolipoprotein B, the pro-protein convertase subtilisin/kexin 9 (PCSK9), and LDLR adaptor protein are the commonest abnormalities. Early identification and treatment of patients, as well as screening of relatives, helps significantly reduce the risk of premature disease. Although statins remain the first-line therapy in most cases, monotherapy is usually inadequate to control elevated LDL-C levels. Additional therapy with ezetimibe and bile acid sequestrants may be required. Newer classes of pharmacotherapy currently under investigation include lomitapide, mipomersen, and monoclonal antibodies to PCSK9. Lipoprotein apheresis may be required when multiple pharmacotherapies are inadequate, especially in the homozygous form. Effective early detection and treatment of the index individual and initiation of cascade screening will help reduce the complications associated with FH. In this article, we review the disease of FH, complexity of diagnosis and management, and the challenges faced in preventing the significant morbidity and mortality associated with it.

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 14, 2015

References

  • Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review
    Austin, MA; Hutter, CM; Zimmern, RL; Humphries, SE
  • Archives of internal medicine, volume 64, October 1939: angina pectoris in hereditary xanthomatosis. By Carl Muller
  • The inheritance of essential familial hypercholesterolemia
    Khachadurian, AK
  • Familial hypercholesterolemia
    Goldstein, JKHH; Brown, MS
  • Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
    Nordestgaard, BG; Chapman, MJ; Humphries, SE
  • Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
    Cuchel, M; Bruckert, E; Ginsberg, HN
  • The LDL receptor
    Goldstein, JL; Brown, MS
  • Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
    Kontush, A; Chapman, MJ
  • Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
    Watts, GF; Gidding, S; Wierzbicki, AS
  • Diagnosis and treatment of familial hypercholesterolaemia
    Hovingh, GK; Davidson, MH; Kastelein, JJ; O’Connor, AM
  • Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication
    Benn, M; Watts, GF; Tybjaerg-Hansen, A; Nordestgaard, BG
  • Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy
    Wadden, TA; Webb, VL; Moran, CH; Bailer, BA
  • Molecular characterization of familial hypercholesterolemia in Spain
    Palacios, L; Grandoso, L; Cuevas, N
  • Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH
    Huijgen, R; Hutten, BA; Kindt, I; Vissers, MN; Kastelein, JJ
  • Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics
    Williams, RR; Hunt, SC; Schumacher, MC
  • Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
    Civeira, F
  • Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
    Versmissen, J; Oosterveer, DM; Yazdanpanah, M
  • Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy
    Raal, FJ; Pilcher, GJ; Panz, VR
  • Familial hypercholesterolaemia: summary of NICE guidance
    Wierzbicki, AS; Humphries, SE; Minhas, R
  • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    Stone, NJ; Robinson, JG; Lichtenstein, AH
  • Colesevelam: a review of its use in hypercholesterolemia
    Robinson, DM; Keating, GM
  • Use of niacin in the United States and Canada
    Jackevicius, CA; Tu, JV; Ko, DT; Leon, N; Krumholz, HM
  • ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    Reiner, Z; Catapano, AL; Backer, G
  • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    Boden, WE; Probstfield, JL; Anderson, T
  • Effects of extended-release niacin with laropiprant in high-risk patients
    Landray, MJ; Haynes, R; Hopewell, JC
  • Fibrates, dyslipoproteinaemia and cardiovascular disease
    Watts, GF; Dimmitt, SB
  • Mechanism of action of fibrates on lipid and lipoprotein metabolism
    Staels, B; Dallongeville, J; Auwerx, J; Schoonjans, K; Leitersdorf, E; Fruchart, JC
  • Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
    Keene, D; Price, C; Shun-Shin, MJ; Francis, DP
  • Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey
    Stefanutti, C; Morozzi, C; Giacomo, S
  • Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia
    Fernandez-Fuertes, LF; Tapia Martin, M; Nieves Pla, I; Novoa Mogollon, FJ; Diaz Cremades, J
  • Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1
    May, C; Berger, JM; Lespine, A
  • Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C; Keech, A; Kearney, PM
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
    Baigent, C; Blackwell, L; Emberson, J
  • A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia
    Marais, AD; Raal, FJ; Stein, EA
  • Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia
    Raal, FJ; Pilcher, GJ; Illingworth, DR
  • Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
    Postmus, I; Trompet, S; Deshmukh, HA
  • Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
    Gagne, C; Gaudet, D; Bruckert, E
  • Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange
    Thompson, GR; Miller, JP; Breslow, JL
  • Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment
    Gennes, JL; Touraine, R; Maunand, B; Truffert, J; Laudat, P
  • A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography
    Lupien, PJ; Moorjani, S; Awad, J
  • Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia
    Stoffel, W; Borberg, H; Greve, V
  • Heart-liver transplantation in a patient with familial hypercholesterolaemia
    Starzl, TE; Bilheimer, DW; Bahnson, HT
  • Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia
    Shirahata, Y; Ohkohchi, N; Kawagishi, N
  • Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late
    Malatack, JJ
  • Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia
    Rader, DJ; Kastelein, JJ
  • Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia
    Wetterau, JR; Aggerbeck, LP; Bouma, ME
  • Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
    Cuchel, M; Meagher, EA; Toit, Theron H
  • Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    Raal, FJ; Santos, RD; Blom, DJ
  • Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial
    Thomas, GS; Cromwell, WC; Ali, S; Chin, W; Flaim, JD; Davidson, M
  • Beyond LDL cholesterol, a new role for PCSK9
    Akram, ON; Bernier, A; Petrides, F; Wong, G; Lambert, G
  • High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
    Welder, G; Zineh, I; Pacanowski, MA; Troutt, JS; Cao, G; Konrad, RJ
  • Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M; Varret, M; Rabes, JP
  • A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol
    Fasano, T; Cefalu, AB; Leo, E
  • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    Cohen, JC; Boerwinkle, E; Mosley, TH; Hobbs, HH
  • PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses
    Benn, M; Nordestgaard, BG; Grande, P; Schnohr, P; Tybjaerg-Hansen, A
  • Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
    Berge, KE; Ose, L; Leren, TP
  • Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
    Koren, MJ; Lundqvist, P; Bolognese, M
  • Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
    Stroes, E; Colquhoun, D; Sullivan, D
  • Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
    Robinson, JG; Nedergaard, BS; Rogers, WJ
  • A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
    Blom, DJ; Hala, T; Bolognese, M
  • Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    Raal, FJ; Honarpour, N; Blom, DJ
  • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    Raal, FJ; Stein, EA; Dufour, R
  • Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes
    Wilson, JM; Chowdhury, NR; Grossman, M
  • A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia
    Grossman, M; Rader, DJ; Muller, DW
  • Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia
    Chen, SJ; Sanmiguel, J; Lock, M
  • Guidelines for the management of familial hypercholesterolemia
    Harada-Shiba, M; Arai, H; Oikawa, S